Posted by Michael Wonder on 25 Feb 2022
NICE draft guidance recommends tucatinib for advanced breast cancer
25 February 2022 - Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib works by blocking a specific area of the HER2 gene in cancer cells, which stops the cells from growing and spreading.
Around 400 people with advanced breast cancer are set to benefit from a new treatment after NICE today published final draft guidance which recommends tucatinib as an option for treating HER2-positive breast cancer that has spread in people who have already tried two or more anti-HER2 treatments.
